Study to Evaluate the Efficacy and Safety of Nintedanib (BIBF 1120) + Prednisone Taper in Patients With Radiation Pneumonitis

PHASE2CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

July 8, 2015

Primary Completion Date

April 12, 2024

Study Completion Date

April 12, 2024

Conditions
Lung CancerLung Metastases
Interventions
DRUG

Nintedanib

DRUG

Prednisone

OTHER

Placebo

Trial Locations (12)

10065

Memorial Sloan Kettering Cancer Center, New York

10604

Memorial Sloan Kettering Westchester, Harrison

11553

Memorial Sloan Kettering Nassau, Uniondale

11725

Memorial Sloan Kettering Cancer Center @ Suffolk, Commack

18103

Lehigh Valley Health Network (Data Collection Only), Allentown

77030

MD ANDERSON CANCER CENTER (Data Collection Only), Houston

84108

Myriad Genetic Laboratory (Data or Specimen Analysis Only), Salt Lake City

02115

Brigham and Women's Hospital (Data Collection Only), Boston

07920

Memorial Sloan Kettering Cancer Center at Basking Ridge, Basking Ridge

07748

Memorial Sloan Kettering Monmouth, Middletown

07645

Memorial Sloan Kettering Bergen, Montvale

Unknown

Memorial Sloan Kettering at Mercy Medical Center, Rockville Centre

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Boehringer Ingelheim

INDUSTRY

lead

Memorial Sloan Kettering Cancer Center

OTHER